肠内给予精氨酸-谷氨酰胺二肽可提高早产儿视网膜病变小鼠模型的视网膜二十二碳六烯酸和神经保护素D1
本研究在氧诱导视网膜病变(OIR)小鼠模型中,于生后第12至17天每日两次灌胃给予精氨酸-谷氨酰胺(Arg-Gln)二肽或溶媒,评估视网膜DHA、神经保护素D1(NPD1)、血管 obliteration、血管密度及视网膜前新生血管。结果示Arg-Gln组视网膜DHA和NPD1升高,视网膜前新生血管较溶媒组减少39±6%(P<0.05),血管密度恢复至73.0±3.0%(溶媒组53.1±3.4%,P<0.05)。作者认为Arg-Gln可能作为更安全、易耐受的营养制剂用于ROP的预防或治疗。
要点
- 在OIR小鼠模型中,生后第12至17天灌胃给予Arg-Gln二肽可升高视网膜DHA和NPD1水平。
- Arg-Gln组视网膜前新生血管较溶媒组减少39±6%(P<0.05),视网膜血管密度恢复至73.0±3.0%(溶媒组53.1±3.4%,P<0.05)。
- Arg-Gln使OIR诱导的信号改变向常氧状态恢复,并伴随胰岛素样生长因子受体1信号正常化、凋亡减少及抗凋亡蛋白增加。
核心结论
- Arg-Gln可能作为更安全、易耐受的营养制剂用于早产儿视网膜病变(ROP)的预防或治疗。
研究设计与样本
- 研究采用氧诱导视网膜病变(OIR)小鼠模型,生后第7天(P7)幼鼠置于75%氧气中5天,P12返回室内空气。
- 幼鼠自P12至P17每日两次灌胃给予Arg-Gln或溶媒,P17取眼进行分析。
- 通过视网膜铺片评估血管 obliteration 和血管密度,通过视网膜切片评估视网膜前新生血管,并检测视网膜DHA和10,17S-二十二碳三烯(神经保护素D1,NPD1)及反向蛋白阵列(RPPA)分析。
主要发现
- Arg-Gln治疗组OIR幼鼠视网膜DHA和NPD1水平升高。
- Arg-Gln组视网膜前新生血管较溶媒对照组减少39±6%(P<0.05)。
- Arg-Gln组视网膜血管密度为73.0±3.0%,溶媒组为53.1±3.4%(P<0.05),Arg-Gln组血管密度恢复。
- Arg-Gln使OIR诱导的信号改变向常氧状态恢复,并伴随胰岛素样生长因子受体1信号正常化、凋亡减少及抗凋亡蛋白增加。
关键数值与推荐
- OIR模型:P7幼鼠置于75%氧气5天,P12返回室内空气。
- 给药方案:P12至P17每日两次灌胃给予Arg-Gln或溶媒。
- 视网膜前新生血管:Arg-Gln组较溶媒组减少39±6%(P<0.05)。
- 视网膜血管密度:Arg-Gln组73.0±3.0% vs 溶媒组53.1±3.4%(P<0.05)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Low levels of the long chain polyunsaturated fatty acid (LCPUFA) docosahexaenoic acid (DHA) have been implicated in retinopathy of prematurity (ROP). However, oral DHA suffers from poor palatability and is associated with increased bleeding in premature infants. We asked whether oral administration of the neutraceutical arginine-glutamine (Arg-Glu) could increase retinal DHA and improve outcomes in a mouse model of oxygen-induced retinopathy (OIR). METHODS: Postnatal day 7 (P7) pups were maintained at 75% oxygen for 5 days and then returned to room air on P12. Pups were gavaged twice daily with Arg-Gln or vehicle from P12 to P17 and eyes were harvested for analysis on P17. Vaso-obliteration and vascular density were assessed on retinal flat mounts and preretinal neovascularization was assessed on retinal cross sections. Retinas were used for measurement of DHA and 10,17S-docosatriene (neuroprotectin D1, NPD1), a key DHA-derived lipid, and for analysis by reverse-phase protein array (RPPA). RESULTS: With Arg-Gln treatment, retinal DHA and NPD1 levels were increased in OIR pups. Arg-Gln reduced preretinal neovascularization by 39 ± 6% (P < 0.05) relative to vehicle control. This was accompanied by a restoration of vascular density of the retina in the pups treated with Arg-Gln (73.0 ± 3.0%) compared to vehicle (53.1 ± 3.4%; P < 0.05). Arg-Gln dipeptide restored OIR-induced signaling changes toward normoxia and was associated with normalization of insulin-like growth factor receptor 1 signaling and reduction of apoptosis and an increase in anti-apoptosis proteins. CONCLUSIONS: Arg-Gln may serve as a safer and easily tolerated nutraceutical agent for prevention or treatment of ROP.
引用
- Shaw LC, Li Calzi S, Li N, et al. Enteral Arg-Gln Dipeptide Administration Increases Retinal Docosahexaenoic Acid and Neuroprotectin D1 in a Murine Model of Retinopathy of Prematurity. Invest Ophthalmol Vis Sci. 2018. PMID: 29490339. doi:10.1167/iovs.17-23034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。